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Abstract — In the last years the development of microfluidic devices enabled infrared micro-spectroscopy 
(IRMS) to be applicable to biological samples. In the present study this method was used to find differences 
between glioma cells and glioma stem cells. The ability of glioma stem cells to initiate new tumor formation 
and their resistance to therapies makes these cells one of the main reasons why the most malignant form of 
glioma – glioblastoma is at present incurable. Several classic markers of glioma stem cells have been reported 
but none of them is their exclusive feature. Here we present preliminary results showing that by applying 
principal component analysis to IRMS data we can separate glioma stem cells and non-stem cells into two 
groups proving the potential of this technique. Further experiments are ongoing. 
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_____________________________________________________________________ 
1 BACKGROUND
Glioblastoma, the most common and aggressive type of brain tumors, remains incurable despite the 
recent progress in diagnostics and treatment of cancer. In the last ten years it has become evident that 
one of the main reasons for unsuccessful treatment and tumor recurrence after surgical resection lies 
in the ability of tumor stem cells – a small subpopulation of tumor cells – to give rise to different cell 
types that then form a tumor bulk. 
It has been recently suggested that differentiation therapy might be a suitable approach to eradicate 
these cells. In this approach, a drug (therapeutic) would be used to induce differentiation of stem cells 
and such differentiated cell, although not dead, would not have the potential to induce new tumor 
formation.
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2 OBJECTIVES
The main objective of the GLIOMA project is to find new markers of glioma stem cells. To be able to 
direct the therapy to these cells and at the same time preserve normal brain function, new methods to 
distinguish glioma stem cells, glioma non-stem cells or non-tumoral cells are needed.
The aim of the present study was to use infrared microspectroscopy (IRMS) to search for possible 
spectral differences between glioma stem and non-stem cells. We also suggest IRMS could be used to 
monitor the differentiating capacity of different compounds. 
3 APPROACH & METHODS
To be able to find differences between glioma cells and glioma stem cells, we have used two model 
cell lines. U251 is a glioblastoma cell line that can be enriched for the stem-cell population by culturing 
in a specific media. NCH421k are glioma stem cell-like cells which by treatment with all-trans retinoic 
acid (ATRA) get differentiated, losing their stem cell properties. 
Each sample was split to two parts and analyzed simultaneously by QPCR and IRMS. Q-PCR was used 
to control the differentiation by measuring expression levels of stem cells markers nestin, CD133 
and glioma marker GFAP. IRMS was used to compare spectral characteristics of stem cells versus 
differentiated cells. All IRMS experiments were done in the collaboration with SISSI-beamline in Elettra-
Sincrotrone Trieste.  
 
IRMS gives information on chemical composition of the cell that is based on detecting vibrations of 
different chemical bonds at corresponding wavelengths. The advantage of IRMS is that cells can be 
analyzed without prior labeling or fixation. A microfluidic system is used to be able to acquire infrared 
spectra of live cells. The device is designed to avoid the saturation of signal to the water contribution 
and to supply fresh buffer to support cell viability. 
Diagnostic and characterization capabilities of IRMS have been largely documented and they are 
based on the multi-screening ability of the technique that gives comprehensive information on 
polysaccharides, lipids, nucleic acids and proteins in a single spectrum. In a recent publication we 
reported on the possibility to determine cell cycle phase of live unlabelled cell by IRMS (Bedolla et. al, 
2013).
109
4 RESULTS
NCH421k and U251 were grown either as neurospheres, where they exert their stem cell properties or 
as monolayer, where they are differentiated.
In order to analyze the data, we used two different mathematical approaches – principal component 
analysis (PCA) and hierarchical cluster analysis (HCA); both of them gave interesting preliminary data 
that prove the potential of this experimental technique. When using the data acquired for the control 
(blue) and the differentiated NCH421k cells after 72h of exposure to ATRA (red), PCA show a grouping 
of the data in two groups.
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5  POTENTIAL NEW PRODUCTS & SERVICES
A final goal of the study is to be able to detect and calculate the proportion of stem cells in a primary 
sample, which is important, since prognosis in glioblastoma correlates with the percentage of stem 
cells. Also, IRMS could be used to test if other agents used to differentiate stem cells result in the same 
spectral changes.
6  CURRENT COLLABORATIONS
Within the GLIOMA project we collaborate with National Institute of Biology, Ljubljana, Slovenia and 
“Santa Maria della Misericordia” Health-University Institute, Udine, Italy.
7  COLLABROATIONS NEEDED
Collaboration with an institution that has access to primary samples is required.
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